ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1478	National Cancer Institute	Html	en	Skin Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of skin cancer.	treatment 0.409923 metastatic basal cell 0.400394 subsequent basal cell 0.391984 Skin Cancer Prevention 0.365074 Arch Dermatol 0.471327 photodynamic therapy 0.399886 sun-exposed skin 0.375699 skin cancers 0.433811 primary skin cancers 0.370681 uncomplicated basal cell 0.398522 basal-cell carcinoma 0.373761 PUBMED Abstract 0.376972 Mohs micrographic surgery 0.406259 Invest Dermatol 0.363857 prior skin cancer 0.363746 multiple basal cell 0.397256 nonmelanoma skin cancers 0.400983 recurrence rates 0.396208 Dermatol Surg Oncol 0.421496 periocular basal cell 0.39808 BCC 0.370104 Abstract 0.389392 main skin cancer 0.382703 basal cell nevus 0.404293	squamous cell carcinomas 0.385705 eyelid addresses carcinomas 0.365517 non-eyelid skin cancers 0.367643 surgical excision 0.369879 Br J Dermatol 0.407426 cosmetic results 0.379562 superficial basal cell 0.487048 skin cancer awareness 0.383438 basal cell carcinomas 0.527823 nodular skin BCCs 0.369486 nodular basal cell 0.432753 nonmelanoma skin cancers. 0.373768 nevoid Basal cell 0.396437 primary superficial basal 0.391239 radiation therapy 0.475907 nonmelanoma skin cancer 0.483068 basal cell carcinoma 0.980145 regional lymph nodes 0.369237 radiation therapy treatment 0.376744 longstanding skin ulcers 0.361677 et al. 0.442813 Acad Dermatol 0.422124 squamous cell carcinoma 0.41423	CLICK HERE
1541	National Cancer Institute	Html	en	Testicular Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of testicular cancer.	tumor marker levels 0.613741 cancer treatment 0.320393 testicle 0.4399 testicular cancer spreads 0.297436 contains cancer cells 0.273957 body 0.340237 PDQ cancer information 0.333395 testicular cancer 0.725943 testicular germ cell 0.272075 clinical trial search 0.331245 long-term follow-up 0.27959 clinical trials 0.622305 undescended testicle 0.275057 cancer information summary 0.310365 clinical trial 0.428741 spermatic cord 0.329024 tumor markers 0.368096 inguinal orchiectomy 0.361937 patients 0.336056 malignant tumor cells 0.300585 NCI PDQ cancer 0.275949 lymph nodes 0.529321 radiation therapy 0.376906 Serum tumor marker 0.305709 general cancer information 0.270473	treatment 0.469864 general information 0.294195 NCI-supported cancer 0.288405 cancer cells 0.405185 Recurrent testicular cancer 0.320003 Cancer Information Service 0.271409 treatment clinical trials 0.292646 National Cancer Institute 0.350045 lymph vessels 0.288149 new treatment 0.293694 distant lymph nodes 0.317031 combination chemotherapy 0.304741 Testicular Cancer Treatment 0.305239 metastatic tumor 0.2721 blood 0.282323 tumor marker test 0.304459 retroperitoneal lymph nodes 0.28218 cancer clinical trials 0.344359 stage 0.329917 testicular tumor 0.289398 comprehensive cancer information 0.269733 cancer 0.908321 information 0.339805 following tumor markers 0.277178	CLICK HERE
1741	National Cancer Institute	Html	en	Menopausal Hormone Therapy and Cancer	A fact sheet about the results of research on menopausal hormone therapy (MHT). Includes information about the effect of MHT on the body and benefits and risks of using menopausal hormones.	M. Menopausal hormone 0.399446 estrogen 0.661955 progestin 0.473666 menopausal symptoms 0.433158 lung cancer 0.436349 postmenopausal estrogen 0.401234 Anderson GL 0.391175 Breast Cancer Research 0.404812 MHT 0.573747 placebo 0.469804 whi estrogen-plus-progestin study 0.43139 colorectal cancer 0.510049 breast cancer survivors 0.442442 vertebral fractures 0.396082 hormone therapy group 0.403745 hormone therapy medication 0.406528 hot flashes 0.474358 invasive breast cancer 0.436727 hormone replacement therapy 0.391432 Health Initiative 0.489409 randomized clinical trials 0.471592 menopausal hormone therapy 0.725067 WHI trials 0.489874 health effects 0.386028 women 0.908896	MHT change 0.392923 breast cancer detection 0.43656 Non-FDA-approved hormone products 0.402601 One-third lower risk 0.39906 breast cancer recurrence 0.408176 breast cancers 0.398762 estrogen-alone MHT 0.393357 10,000 women 0.558208 National Cancer Institute 0.442573 natural hormones estrogen 0.458568 hormone therapy 0.86696 combined hormone therapy 0.473354 postmenopausal women 0.502051 absolute terms 0.40498 breast cancer 0.990788 WHI Estrogen-Alone Study 0.441842 Chlebowski RT 0.451885 randomized controlled trial 0.389145 healthy postmenopausal women 0.397371 et al 0.576891 New England Journal 0.390547 breast cancer incidence 0.436953 Women’s Health 0.429633 risk 0.448458	CLICK HERE
1951	National Cancer Institute	Html	es	Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos.	siguientes procedimientos 0.408317 displasia multilinaje 0.404818 células madre 0.698581 leucemia aguda 0.40611 síndromes mielodisplásicos 0.99284 hueso compacto 0.416921 neoplasias mieloides 0.402645 plaquetas maduras 0.410918 célula madre mieloide 0.437557 National Cancer Institute 0.402744 siguientes riesgos 0.401921 vitamina b12 0.403995	Instituto Nacional 0.404912 PDQ Tratamiento 0.439829 célula madre linfoide 0.43173 vidrio piezas 0.403146 neoplasias mielodisplásicas 0.404775 displasia unilinaje 0.404747 Physician Data Query 0.410747 cáncer.ampliar trasplante 0.403337 leucemia mieloide aguda 0.59748 célula madre 0.50311 células sanguíneas maduras 0.465531 siguientes pruebas 0.40454	CLICK HERE
2110	National Cancer Institute	Html	es	Exámenes de detección del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de esófago.	upper gastrointestinal tract 0.43004 Cancer Research Fund 0.484546 brush cytology as 0.429018 Lagergren J 0.555033 Gastrointest Endosc 0.477141 American Cancer Society 0.678403 stains intestinal metaplasia 0.429485 oesophagus along caspian 0.427264 gastroesophageal reflux 0.489709 fármacos relajantes 0.451925 Spechler SJ 0.485427 Symptomatic gastroesophageal reflux 0.437613 Instituto Nacional 0.453917 brush off this 0.427799 Dawsey SM 0.483008 Bergström R 0.555203 PDQ Exámenes 0.458666 Estados Unidos 0.464483 Natl Cancer Inst 0.581715 múltiples estudios 0.436926 intestinal metaplasia 0.447925 Blot WJ 0.441725 Aliment Pharmacol Ther 0.427038 esophageal cancer 0.945046 gastrointestinal tract 0.444979	Endoscopic Screening Study 0.437695 Barrett quizás 0.452361 does lugol staining 0.427191 Cancer Facts 0.485513 Petras RE 0.445899 hallazgos histológicos simultáneos 0.432023 villas norteñas vs 0.429133 Norman Barrett 0.453271 riesgo quizás 0.428246 pan-esophageal brush cytology 0.43018 Cancer Research 0.525303 National Cancer Institute 0.476234 gastric carcinoma 0.452643 Epidemiol Biomarkers Prev 0.482868 Thorac Cardiovasc Surg 0.430717 alcoholics using endoscopy 0.428611 Intern Med 0.449117 outpatient gi endoscopy 0.428057 seroepidemiologic case-control study 0.429272 risk factor 0.46512 prospective follow-up study 0.432873 squamous cell dysplasia 0.434246 brush cytology 0.443313 Preoperative risk analysis 0.436183	CLICK HERE
3435	National Cancer Institute	Html	es	Riesgo de cáncer de seno en mujeres estadounidenses	Hoja informativa que presenta estadísticas sobre el riesgo que tiene una mujer de padecer cáncer de seno (mama) e información sobre los factores de riesgo del cáncer de seno.	Risk Assessment Tool 0.544579 familiar masculino 0.474027 siguientes estimaciones 0.491803 siguientes factores 0.486246 carcinoma lobulillar 0.472032 Estados Unidos 0.992188 Determinados cambios 0.507031 abortos espontáneos 0.47065	características anormales 0.475549 largo plazo 0.483682 Antecedentes familiares 0.466654 determinados genes 0.674691 mujer estadounidense promedio 0.835519 SEER Cancer Statistics 0.593996 fármaco des 0.469829	CLICK HERE
3651	National Cancer Institute	Html	en	TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence May Forgo Chemotherapy	A summary of results from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.	adjuvant chemotherapy 0.787463 higher recurrence scores 0.454387 21-gene recurrence score 0.676351 mid-range score 0.364833 postsurgical chemotherapy 0.404675 Jo Anne Zujewski 0.399515 Cancer Therapy Evaluation 0.426635 National Clinical Trials 0.404942 adult cancer research 0.415943 early-stage breast cancer 0.44803 Montefiore Medical Center 0.406438 test’s ability 0.364803 lowest 21-gene recurrence 0.476043 patients 0.383684 5-year recurrence rates 0.497417 Trial Assigning Individualized 0.434763 hormone receptor-positive breast 0.606376 gene panel test 0.401972 high risk 0.363068 primary breast cancers 0.421261 women 0.592588 low risk 0.421557 United States 0.429126 ECOG-ACRIN Research Group 0.402947	low-risk subset 0.454616 breast cancer recurrence 0.516723 percent 0.443551 Initial findings 0.364086 hormone receptor-positive disease 0.474523 10,000 women 0.389687 molecular test 0.368711 21-gene panel test 0.405027 various treatment options 0.412166 hormone therapy 0.89376 aromatase inhibitor therapy 0.427967 primary cancer events 0.412638 NCIC-Clinical Trials Group 0.404753 postoperative treatment 0.371444 estrogen receptor 0.368053 early-stage hormone 0.432936 breast cancer 0.917923 21-gene recurrence test 0.48221 Recurrence events 0.412295 breast cancer mortality 0.453698 -positive breast cancer 0.464645 New England Journal 0.424409 HER2-negative breast cancer 0.446932 journal article 0.367547	CLICK HERE
15774	National Cancer Institute	Html	en	Cancer Clinical Trials API	Access NCI-supported cancer clinical trials information through an application programming interface (API).	IND/IDE information 0.322332 search tools 0.31747 initial working piece 0.395837 clinical trial information 0.444384 application programming interface 0.438002 developers 0.217415 CTRP information 0.321432 questions 0.217374 Clinical Trials Reporting 0.43587 NCI-supported cancer 0.32979 biomarker data 0.321606 feedback 0.238876 clinical trial search 0.427355 database 0.218238 academia 0.222589 NCI-specific Data Table 0.401719 individual communities 0.317208 contact 0.217352 large amounts 0.326709 clinical trials 0.959644 family members 0.316516 summary 0.217584	community—advocacy groups 0.318407 ct-api-support@nih.gov. 0.306404 Clinical Trials API 0.843331 beta version 0.313025 https://clinicaltrialsapi.cancer.gov 0.217378 meaningful ways 0.325497 regulatory information 0.322729 common language 0.320268 patients 0.239672 Documentation 0.217429 digital platforms 0.317392 public web 0.304451 help 0.217404 better search results 0.40957 cancer clinical trials 0.743102 IRB approval details 0.415735 accrual information 0.335388 oncologists 0.229097 integrations 0.227372 providers 0.219039 Trials Beta API 0.505116	CLICK HERE
16693	National Cancer Institute	Html	en	In an Era of Precision Medicine, Testing New Approaches to Breast Cancer Screening	An NCI research article about individualized approaches that could help identify those at risk of breast cancer who need to be screened and testing screening intervals that are appropriate for each person’s level of risk.	clinical DNA testing 0.255296 certain genetic alterations 0.26295 Family Comprehensive Cancer 0.304528 early molecular changes 0.250583 Breast Cancer Surveillance 0.393407 Dr. Szabo 0.324259 Breast Care Center 0.362601 ovarian cancer patients 0.316413 clinical trial 0.331236 breast cancer prevention 0.392842 breast density 0.431317 annual mammography 0.280302 risk-based group 0.308284 breast MRI 0.280239 Dr. Tice 0.272786 molecular changes 0.271002 seminal clinical trials 0.251623 Consortium Risk Calculator 0.280953 risk-based approach 0.302169 high risk 0.287254 precision medicine 0.358439 genetic markers 0.26055 women 0.30866 risk-based screening arm 0.644595 annual mammograms 0.27926	hereditary breast 0.275314 cancer screening 0.642713 cancer prevention 0.415329 HBOC—for genetic alterations 0.253144 risk-based screening strategies 0.470957 advanced-stage breast cancers 0.351274 family medical history 0.264412 General Internal Medicine 0.258705 Cancer MoonshotSM Blue 0.314025 risk-based screening 0.987559 false-positive test results 0.2742 lowest risk scores 0.302649 strongest risk factor 0.279896 breast cancer risk 0.568335 screening interval 0.333337 breast cancer 0.836019 genetic alterations 0.266377 annual screening group 0.404487 risk factor 0.298033 precision cancer prevention 0.325999 risk prediction model 0.28587 WISDOM trial 0.343878 highest risk scores 0.301801 ovarian cancer syndrome 0.315021	CLICK HERE
16829	National Cancer Institute	Html	en	Cancer Driver Discovery Program	null	large number 0.638311 tumor biology 0.66038 rare driver events 0.719635 comprehensive genomic characterization 0.740363 genomic analyses 0.633135 patient responses 0.721865 tumor tissues 0.638276 additional driver mutations 0.771411 lung cancer 0.952268 statistical models 0.628862 statistical power 0.629897 cancer genomics 0.65394 recurrent mutations 0.655852 patients 0.702611 Genomic Data Commons 0.762952 clinical trial N0147 0.722969 Lung Cancer project 0.792668 molecular causes 0.642033 oncogenic process 0.640394 public health impact 0.739202 epidermal growth factor 0.708102 tumor types 0.658904 Cancer Driver Discovery 0.8155 DNA sequencing 0.651327 Cancer Research UK 0.776689	RNA sequence 0.636519 associated follow-up information 0.721592 ovarian cancers 0.639935 better treatment options 0.776737 clinical outcomes 0.638824 Foundation Lung Cancer 0.793933 intratumoral heterogeneity 0.742723 deeper characterization 0.652385 TRACERx collaborators 0.637079 NCI-funded clinical trial 0.73112 Genome Characterization Pipeline 0.748856 driver mutations 0.919706 St. James 0.824605 Tracking Cancer Evolution 0.775958 CCG 0.851349 colon cancer 0.744767 lung adenocarcinoma 0.669686 TRACERx study 0.634122 total RNA sequencing 0.961331 Cancer Genome Atlas 0.832019 chemotherapy regimen 0.639583 particular lung cancer 0.807795 Central Cancer Treatment 0.762707 genome sequencing 0.685209	CLICK HERE